Drzymała-Czyż S, Dziedzic K, Szwengiel A, et al. - Researchers assessed serum bile acid concentrations in cystic fibrosis (CF) to determine their utility in liver disease evaluation. In three CF groups (25 patients each) showing: liver cirrhosis, other liver disease, no liver disease, as well as in 25 healthy subjects (HS), measurements of primary, secondary and conjugated bile acid levels were obtained. Higher bile acid concentrations were detected in CF patients vs in HS, except for glycodeoxycholic acid (GDCA). However, no difference in bile acid levels existed between patients with cirrhosis and other liver involvement. Overall, a CF-specific bile acid profile was described and demonstrated to associate with liver disease. Differentiation of cases with non-cirrhotic liver involvement from those with no identifiable liver disease was enabled by GDCA. Therefore, GDCA merits validation as a biomarker of non-cirrhotic progression of liver disease in CF.